U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07202598) titled 'A Phase 2 Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis' on Oct. 01.
Brief Summary: Study Description:
This is a phase 2 randomized stepped wedge open-label study to evaluate the efficacy and safety of the anti-interferon-gamma (IFN-gamma) monoclonal antibody, emapalumab, in autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy (APECED) enteritis. Qualifying participants will be randomized to initiate emapalumab at 0, 2, 4, or 6 months post-baseline visit. They will be admitted for up to 10 days for an inpatient visit to start receiving emapalumab in 2 intravenous (IV) infusions 3 days apart. Thereafter, p...